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Abstract— Medication non-adherence is a widespread
problem affecting over 50% of people who have chronic illness
and need chronic treatment [1]. Non-adherence exacerbates
health risks and drives significant increases in treatment
costs. In order to address these challenges, the importance of
predicting patients’ adherence has been recognised. In other
words, it is important to improve the efficiency of interventions
of the current healthcare system by prioritizing resources to the
patients who are most likely to be non-adherent. Our objective
in this work is to make predictions regarding individual
patients’ behaviour in terms of taking their medication on
time during their next scheduled medication opportunity. We
do this by leveraging a number of machine learning models.
In particular, we demonstrate the use of a connected IoT
device; a “Smart Sharps Bin”, invented by HealthBeacon
Ltd.; to monitor and track injection disposal of patients in
their home environment. Using extensive data collected from
these devices, five machine learning models, namely Extra
Trees Classifier, Random Forest, XGBoost, Gradient Boosting
and Multilayer Perception were trained and evaluated on a
large dataset comprising 165,223 historic injection disposal
records collected from 5,915 HealthBeacon units over the
course of 3 years. The testing work was conducted on real-time
data generated by the smart device over a time period after
the model training was complete, i.e. true future data. The
proposed machine learning approach demonstrated very good
predictive performance exhibiting an Area Under the Receiver
Operating Characteristic Curve (ROC AUC) of 0.86.
I. INTRODUCTION
Medication non-adherence is a major concern worldwide.
According to a report from the World Health Organisation
(WHO) [1], only 50% of people adhere to their chronic
therapy. Such poor medication adherence can affect the
effectiveness of prescribed treatments, increasing safety risks
for patients and creating unnecessary financial burden for
the clinicians, healthcare industry and other stakeholders
[2]. In this paper, adherence is defined as the degree to
which the person’s behaviour corresponds with the agreed
recommendations from a health care provider [1]. In order
to solve the problem of non-adherence, the first challenge to
overcome is selecting an accurate method of measuring and
monitoring patient adherence. A wide range of adherence
measurement approaches have been reported in the literature
[3], and these can be classified into two categories: the
indirect method and the direct method. In particular, indirect
methods include pill counts, self-reported questionnaires and
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Medication Event Monitoring System (MEMS). MEMS is
considered the gold standard in terms of existing adherence
measurement approaches and works through tracking the
dates and time stamps when the patients open the bottle cap
[4]. Compared to MEMS, adherence was roughly overesti-
mated by 17% using self-report and 8% using pill counts [5].
The benefits of the self-report method are that it is both easy
and straightforward for the patient. However, as the reported
adherence can be biased by patients’ inaccurate recall, thus
the adherence is significantly overestimated [6]. Even the
gold standard MEMS approach faces some challenges, such
as the potential for loss of data and limited user acceptance;
some patients reported that they found it difficult to transfer
medication into the MEMS bottle [7]. Direct methods include
measurement of drug levels in body fluids such as plasma
and urine. The accuracy of this method may be influenced by
drug metabolism so patterns of adherence cannot be obtained
in this way. Moreover, direct observations can only be taken
from hospitalized patients, so is not of relevance to those
who take medications in a home setting.
Many medications for illnesses like arthritis, diabetes and
multiple sclerosis are self-administered by injection at the
patient’s home: away from a supervised healthcare provider’s
environment. In order to better measure patient adherence
and manage these self-administered injections, HealthBeacon
have developed a connected IoT device, the “Smart Sharps
Bin” (SSB). HealthBeacon is a digital medication technology
company that develops smart tools for managing medication.
The SSB is suitable for use in a home setting and digitally
records the disposal of used hypodermic needles, passively
tracking injection disposal data and uploading it to a cloud-
based database for long-term storage and further analysis to
enable the support team to monitor the drop disposals and
provide follow-up services as necessary. The use of the SSB
doesn’t require any major alteration to standard hypodermic
needle disposal behaviour, and brings additional benefits to
the patient: the system prompts the patient when their next
injection is due and reports their medication adherence status,
without the need for direct interaction with the healthcare
provider. The SSB has FDA clearance and has been inte-
grated into patient care programs throughout North America
and Europe. It can therefore be considered as state of the
art technology for measuring patients’ adherence accurately
and efficiently. In order to improve the patient adherence
rate, precise measurement of medication adherence and the
use of appropriate intervention methods (by the healthcare
system) are important. Another key factor in this context is
about predicting the accuracy of patient adherence in the
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future. If the patients that are most likely to be non-adherent
can be accurately identified and targeted, the efficiency of
interventions can be significantly increased [8], [9]. Non-
adherence is a multifactorial problem that can be influenced
by a range of patient-, disease-, condition-, social/economic-
and healthcare system-related factors [10]. It is common for
patients to be confused by treatment schedules, forget to
take their medications due to unexpected events, discontinue
to take their medication due to side effects, or stop taking
the treatment because they feel they no longer need it.
For predicting patient adherence, significant effort has been
devoted to investigation of the correlation or relationship
between these various factors and the level of adherence [11],
[12]. In the work by Schuz et al. [13], the authors attempted
to predict patient adherence by analysing medication beliefs,
showing that a patient’s beliefs about medication affect both
intentional and unintentional treatment adherence. Stilley et
al. [14] predicted patient adherence based on patient-related
features such as gender, age and race. While many of these
features correlate with patient adherence, they demonstrate
weak discrimination between adherers and non-adherers. In
contrast, prediction of adherence based on prior pill refill
data achieved higher accuracy [15], illustrating that historic
adherence records contain more accurate predictive informa-
tion of future patient treatment adherence. More recent work
has applied emerging machine learning techniques rather
than analysis of patient characteristics to predict patient
adherence. In a small scale study of Parkinson’s disease
patients, Tucker et al. [16] predicted patient adherence by
adopting a remote data mining approach to analyse whole-
body movement data collected by a non-wearable hard-
ware device, and subsequently classifying the patient using
machine learning methods. Karanasiou et al. [17] applied
eleven classification algorithms such as SVM and Bayesian
Networks to predict the adherence of patients with heart
failure based on a dataset of 90 patients, and Franklin et al.
[18] aimed to predict patient adherence in the next 30, 60 and
90 days using ten different machine learning models based
on information from Medicare enrolment files and medical
and pharmacy claims.
In this work, historic hypodermic disposal data collected
from patients’ SSBs has been selected as the primary vari-
able for adherence prediction; analysis of the importance
of various different data features (features generated by
HealthBeacon’s SSB and management system) in terms of
future adherence prediction is discussed in detail below.
Using a large dataset with 5,915 HealthBeacon units and
165,223 historic hypodermic drop records over a three year
period, a patient adherence prediction model was developed.
To the best of our knowledge, this work is the first machine
learning-based prediction model to date to be developed
using an extensive, real patient dataset. Specifically, our work
has 3 main contributions:
(i) We proposed and developed the SSB, a connected
IoT device, which can be used to record a patient’s
historic hypodermic drops (referred to as a ‘drop’ from
hereon in, drop is defined as the event of disposing
the hypodermic medication into SSB) and monitor
patient adherence in their own home. The raw dataset
collected through the SSB contains a substantial
amount of valuable data with various features including
drop date/timestamp.
(ii) We trained and developed machine learning models
in an end-to-end fashion using the data collected by
the SSB. We propose an ensemble learning system
that combines 5 different machine learning models to
generate an adherence prediction model capable of
predicting a patient’s adherence at their next scheduled
medication event.
(iii) We performed experiments and testing on real world
self-medicating patient data from a unseen dataset and
demonstrated that our approach achieved both excellent
prediction performance and good generalisation with an
accuracy of 81.24% and an AUC of 0.86, respectively.
Technical details of the “Smart Sharps Bin” are given
in Section II, the methodology of machine learning model
construction is presented in Section III, and the testing work
and results are discussed in Section IV. General conclusions
can be found in Section V.
II. DATA COLLECTION: THE SMART SHARPS BIN (SSB)
The SSB is an injectable medication management system
which can be easily integrated into a patient’s home and
constantly monitor the medication disposal. For further
clinical intervention, we predicted the patient medication
adherence by leveraging machine learning models based on
the real time data collected from the SSB. The device was
launched in May 2015 by HealthBeacon Ltd., and since
then it has been used by 9,000+ patients and has tracked
300,000+ disposed hypodermic needles.
A. SSB Technical Details
The SSB has been designed as a cuboid and consists
of five main parts, as shown in the schematic diagram in
Figure 1. The uppermost surface contains an LCD screen
and an integrated sharps bin lid. When a patient starts
a treatment programme suitable for at-home medication
through injection, an SSB is dispatched to the patient, pre-
programmed with their personal medication schedule infor-
mation, including information such as the scheduled start
date, injection frequency, required injection location (area
of body) and preferred short message service (SMS) time
slots. When an injection is due, the blue light notification
above the LCD screen lights up as a visual reminder for
the patient. Along with this, a reminder SMS is sent to the
patient at their preferred time slot. If the patient fails to
take their medication/forgets to drop it into the HealthBeacon
SSB, an intervention SMS is issued the following day. The
SMS’ reminder system works in a smart way as it only
triggers SMS when required. The left zone of the LCD screen
shows the adherence score of the patient: initialized as 0%
at the very beginning of the treatment, the score increases
or decreases according to patient’s adherence rate over a
given period, to encourage the patient to stay on track with
their medication. When the patient is ready to inject, they
administer the medication at the injection location shown
on the LCD screen. After injection, the patient disposes
of the used injector by pushing it through the bin lid (a
traditional hazardous sharps bin sits inside the SSB). When
an injection is dropped into the SSB, a sensor beam which
is fitted inside the lid is tripped and triggers a micro-camera
inside the SSB to capture a picture of the injection along
with a time stamp. For each drop, 2 files are created: a
.csv file containing the time stamp and a .bmp file with
the image. The files are then uploaded to HealthBeacon’s
cloud server through a secure private Access Point Name
(APN) via a Machine to Machine (M2M) simcard. All data
is encrypted both in transit and rest based on Advanced
Encryption Standard (AES) 256 . The unstructured dataset
is finally uploaded to Amazon Simple Storage Service (S3)
for long-term storage while the dataset saved as CSV files
is migrated to Amazon Relational Database Service (RDS).
Complimentary to the SSB data, a web application has been
developed where patients’ limited personal data including
age, name, medication type and injection frequency can be
collected for programming the SSB set-up for each patient.
Fig. 1: A schematic diagram of the HealthBeacon SSB.
III. METHODOLOGY
A. Data Extraction and Preprocessing
HealthBeacon’s cloud-based database includes informa-
tion regarding patients and their trearment programme, from
the scheduled medication date and frequency for each pa-
tient to the drop status of scheduled injections. The dataset
used for training the predictive machine learning models
was collected from the 7th May 2015 to 27th Oct 2018,
inclusive. The dataset contains information obtained from
5,915 HealthBeacon units, including 165,223 individual drop
events. The data was retrieved and exported from the
database in the format of CSV files for further processing.
Only the essential anonymised data fields from the web
application were extracted in order to comply with EU
General Data Protection Regulation (GDPR) policies [19].
The dataset was then cleaned to remove empty rows/columns
and redundant variables. Categorical data other than drop
status was transformed into a machine learning-compatible
format using one hot encoding. One hot encoding is a
classic technique applied in machine learning that converts
categorical variables into a form that is suitable for provision
to machine learning algorithms.
The time stamp of the drop status has been converted
to labels as “On-Time” / “Not On-time” based on the time
difference between the drop time stamp and the scheduled
medication time stamp.
We define the recommended time period for medication
by the medical prescription as ”Window for Medication
Administration (WMA)” in this paper. WMA varies by
different drugs and different scheduled medication frequency.
In the context of this work, the drop was labelled as “On-
Time” if the medication was taken within the window in
SSB, otherwise, the drop was marked as “Not On-time” if the
medication was taken outside the window or never dropped
in the SSB at all. Thus, the problem has been formatted as
a binary classification problem. WMA and the drop status
labels are shown in Figure 2.
Fig. 2: The time frame defined for “On-Time” and “Not-On-
time” disposals.
B. Feature Selection
The next step was to decide which features should be
taken into account for this problem and then feed them into
machine learning models. Firstly, in order to select impor-
tant features, we used Waikato Environment for Knowledge
Analysis (WEKA) [20], an open-source software containing
a collection of visualization tools and algorithms for data
analysis and machine learning modelling. WEKA helped to
filter out any uncorrelated features, only selecting important
features that contain the best predictive information using
the information gain-based feature selection technique and
the built-in ’InfoGainAttibuteEval’ attribute evaluator. After
running the evaluator on the entire training dataset, the
selected features can be mainly classified as historic drops,
medication frequency and country.
It was observed that patient drop history is the most
significant feature, with the most recent drop being the most
important. Thus, historic drop data was taken as a very
significant attribute for prediction of medication adherence.
In order to decide the number of historic drops to take into
account as features, we incrementally increased the number
of historic drops from 5 to 14 and attempted to predict
the status of the next drop. Moreover, we calculated the
ROC AUC score, varying the number of drops from 5 to
14 evaluated on Random Forest algorithm. The performance
of the Random Forest model was evaluated by progressively
increasing the number of drops from the last (most recent)
five drops up to the last fourteen drops. The ROC AUC score
was plotted in Figure 3, and shows that the ROC AUC score
is largest when six historic drops are taken into account.
Thus, we chose to use the last 6 historic drops in order to
predict patient adherence for the next scheduled medication
event. Therefore, the units with less than 7 historic drops
attached to their record were removed from the dataset. This
reduced the number of samples in the training set to 160,865
(drops) associated with 4,609 units.
Fig. 3: The ROC AUC score versus the number of drops.
The ROC AUC was computed based on the Random Forest
model by incrementally selecting a number of historic drops
ranging from 5 to 14.
Furthermore, the top 10 most important features have
been plotted by using the Extra Trees Classier algorithm in
Figure 4, and the accumulated importance of features is also
demonstrated in Figure 5. From these two Figures, it is clear
that historic drops are the dominant features, constituting
99% of the feature importance, meaning that historic drop
data contains the most useful predictive information, while
the second most important feature is medication frequency.
Here frequency at which patient is scheduled to administer
their injection at a regular basis, for example, once a week
or daily.
C. Modelling and Hyper-parameters Tuning
Firstly, we split the entire dataset into two subsets: training
set and validation set. In our project, the training data set was
used to fit a group of candidate machine learning models and
the validation set was used to optimize the models by tuning
parameters and hyper-parameters. The total dataset was split
and allocated randomly between these two categories with
the following proportion: 80% for training set and 20% for
validation set.
Fig. 4: The top 10 most important features, selected using
Extra Trees Classifier. Note that “latest drop” in this figure
refers to the drop the patient disposed in last scheduled date
while “earliest” means the first drop made in the sequence
of 6 historic drops. “f” stands for frequency and “NA” is the
abbreviation of North America.
Fig. 5: The accumulated importance of all features (NA:
North America, EU: European Union, AS: Asia, AF: Africa,
AN: Antarctica, SA: South America, OC: Oceania).
The main objective of this project was to predict a
binary classification of whether a patient is going to
take medication “On-Time” (within the WMA) or “Not
On-Time” (outside the WMA). To increase the prediction
accuracy and to avoid the risk of overfitting, we selected,
constructed and evaluated several standard ensemble
learning models and artificial neural networks. Ensemble
learning combines multiple machine learning models for
better predictive performance and decreased likelihood of
overfitting (lower variance), as different models generally
do not make all of the same errors on the testing set [21].
The hyper-parameters for the models were optimised by
applying both Random Search and Grid Search with the
10-fold cross validation method. After evaluation using
the validation dataset, we selected the top five performing
models: Extra Trees Classifier, Random Forest, XGBoost,
Gradient Boosting and Multilayer perception. Furthermore,
we combined these five models and proposed a majority
voting architecture where the majority of the prediction
results obtained from the five models will be adopted as the
final result. For instance, if the prediction results from the
five models are displayed as: “On-Time”, “Not On-Time”,
“Not On-Time”, “On-Time” and “On-Time”, the final
prediction result would be “On-Time” as the result included
three occurances of “On-Time” compared to two counts
of “Not On-Time”. A schematic diagram illustrating this
process is shown in Figure 6. We used Scikit-learn [22],
a free open-source machine learning library for Python,
to construct the machine learning models and search for
optimal parameters and hyper-parameters.
Fig. 6: The ensemble learning and majority voting system.
We selected the majority of the binary prediction results as
final result through the voting architecture.
D. Model Evaluation and Testing
Drop data was recorded by the SSB and uploaded to the
database for storage on a daily basis. This daily-generated
dataset was retrieved for the period from 20th December
2018 to 7th March 2019 and used as the testing dataset,
as using data previously unseen by the models means that
the testing work is free from ‘data leak’ problems. During
this period, for patients expected to take medication, the
‘Prediction file’ containing the historic drop information of
the six most recent drops was collected at the beginning of
the scheduled medication day. This data was used to predict
if the 7th (next) drop would be “On-time” or “Not On-
time”. Once the ‘Prediction file’ had been extracted, it was
fed to the proposed machine learning models in order to
predict which category of classification (“On-Time” / “Not
On-Time’) would be allocated to the patient that day.
As we mentioned above, WMA is the recommended time
range within which a drug should be administered. The
WMA can vary for different drugs and also for different
scheduled medication frequencies. For one drug type in-
volved in the study the adherence window is 144 hours,
which means all drops made within 72 hours of the scheduled
medication time were labelled as “On-Time”, in this case, in
order to give patients enough time to take medication and
dispose of the used injector, the ‘Testing file’ (including the
ground truth on the real behaviours of patients) was collected
72 hours after the scheduled medication day. The testing
work compared the ‘Prediction file’ with the ‘Testing file’.
For simplicity, we assume an example where a patient is
scheduled to take medication on the 5th January 2019; the
‘Prediction file’ is generated at 12 am on the 5th January
2019 and contains data from the last 6 drops; if the window
is 144 hours, the ‘Testing file’ with the real-world drop result
is then collected at 12 am on 8th January 2019. During the
period from 12 am on 2nd January to 12 am on 8th January, if
the patient takes the medication and makes the right disposal
within the 144 hours, the behaviour can be labelled as “On-
Time”, otherwise, the drop is classified as “Not On-Time”.
This data was recorded in ‘Testing file’ as ground truth for
further testing work.
Before conducting the testing work, we removed data
generated in the following scenarios:
• Unplugged: if the patient’s unit is unplugged for a
period of more than 30 days before the scheduled
medication drop day. Please note that in principle the
SSB is required to remain plugged in all the time
for constant monitoring. However, we consider it as
unplugged when the unit is not communicating for a
period of more than 30 days.
• Deactivated: if the patient’s unit is deactivated in the
period between extraction of the ‘Prediction file’ and
‘Testing file’ (excluded from the dataset due to insuf-
ficient knowledge regarding the ground truth of the
patient’s test drop).
• Self-Reported: In an event of the patient being away
from the SSB, their drop status can be reported inde-
pendently after the scheduled drop time. Inclusion of
self-reported drops/amended drops are not suitable as
there is too much uncertainty in patient behaviour and
only the accurate drop information is considered as the
ground truth for testing.
• Loading Dose: a loading dose is an initial higher dose
of medication or series of such doses given in order to
rapidly achieve a therapeutic concentration in the body.
Loading doses were excluded as it would introduce a
bias in predicting the future drops.
IV. RESULTS
In testing work, we evaluated the machine learning models
by generating both a ROC curve and a confusion matrix
for better illustration. The ROC curve in Figure 7 shows
the AUC score of the predictive model to be 0.86 on the
testing set. From the confusion matrix (the confusion matrix
and additional performance metrics are illustrated in Figure
8) we can see 26,624 drops after exclusions were used
for prediction. Among these, 21,631 drops were predicted
correctly by using our trained models: a prediction accuracy
of 81.24% on the testing set. In addition, the recall/sensitivity
from the confusion matrix is 91%, which shows 91% of
the prediction made on those who will take medication on
time (“On-Time” type) is correct based on the constructed
models. While the specificity exhibits the ratio of the correct
prediction made on the people who will not take medication
on time (“Not On-Time” type) is 62%. In the real world, our
objective is predicting which patients are likely to not adhere
to the medication so that interventions can be introduced to
this group before the scheduled medication day in an attempt
to improve the adherence rate. In other words, the prediction
accuracy of these who are “Not On-Time” is more important
in the case. Consider the number of samples in the “On-
Time” class in our training set exceeded the “Not On-Time”
class: the class imbalance can bias models to the majority
class. In order to neutralize this, we retrained the models by
randomly under-sampling the majority class. The confusion
matrix generated from the retrained model in Figure 9 shows
the specificity increases from 62% to 83% after resampling,
which means that 83% of patients who didn’t take medication
on time were predicted correctly according to the retrained
model.
Fig. 7: ROC curve for performance on the testing set (AUC
= 0.86).
Fig. 8: The confusion matrix generated for the testing set,
with evaluated metrics.
In order to test if the constructed model is overfitting
or underfitting, we generated ‘Learning Curves’ as a
diagnostic tool by plotting and comparing the performance
of the proposed model on both the training set and testing
set. ‘Learning Curves’ are plots that show changes in
learning performance over time in terms of experience
[23]. By incrementally adding training samples, the model
Fig. 9: The confusion matrix generated for the testing set
after resampling.
performance can be evaluated on both the training dataset
and a hold out testing set after each update during the
training process. In this work, we progressively increased
the size of the training dataset from 100 training samples
to 130,000 training samples for constructing the model,
and then plotted the model performance on the training set
and testing set versus dynamic training size. The accuracy,
precision and F1 score have been selected as performance
metrics and each metric has been plotted in Figure 10. The
‘Train Learning Curve’ demonstrates how well the model is
learning and the ‘Test Learning Curve’ gives an indication
of the generalization performance of the model on unseen
data. Based on this, an ideal result would be for the offset
between these two lines to be as small as possible. We
can see from the Figures that the offset between the two
plots is very small. The concrete performance metrics are
listed in more detail in Figure 11. These values show the
accuracy, precision and F1 score on both the training set
and testing set at selected specific iterations: 100, 25,000,
50,000, 75,000, 100,00 and, 130,000. Figure 11 also shows
that the offset between the training and testing dataset based
on accuracy, precision and F1 score are 4.43%, 5.9% and
1.9% respectively, which illustrates the constructed model
is in general a good fit with suitable generalisation ability.
V. CONCLUSION
In this paper, we presented a novel machine learning
approach to predict patient treatment adherence using a large
and reliable dataset comprising 165,223 historic injection
disposal records collected from 5,915 HealthBeacon SSB
units. The machine learning model construction methodology
was discussed in detail and the proposed approach was
validated by generating and evaluating various performance
metrics on a real-world testing set.
We demonstrate that HealthBeacon SSB data can be used
to predict if a patient is likely to fail to take their medication
on time with an accuracy of 81.3%. The model demonstrated
(a) Model performance based on ‘Accuracy’.
(b) Model performance based on ‘Precision’.
(c) Model performance based on ‘F1 score’.
Fig. 10: Learning curves on both the training and testing
dataset. The x-axis represents the number of training samples
and the y-axis shows the performance of machine learning
model.
very good performance in predicting patient adherence with
a ROC AUC score of 0.86 for a new patient dataset.
The results of this study validate that the data collected
from the HealthBeacon SSB in combination with a machine
learning model provides an accurate way of identifying
patients who are at risk for future non-adherence. These
valuable insights will enable targeted patient interventions.
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